3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
64
Colonic Neoplasms
19
Rectal Neoplasms
12
Esophageal Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Cholangiocarcinoma
7
Squamous Cell Carcinoma of Head and Neck
6
Pancreatic Neoplasms
6
Breast Neoplasms
6
Colorectal Cancer Metastatic
5
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Inflammatory Breast Neoplasms
3
Carcinoma, Squamous Cell
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Glioma
2
Gastrointestinal Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Tumors
1
Interventions
Cisplatin
86
Radiotherapy
71
Paclitaxel
50
Fluorouracil
38
Carboplatin
36
Drug Therapy
32
Neoadjuvant Therapy
23
toripalimab
19
tislelizumab
18
pembrolizumab
17
camrelizumab
17
Irinotecan
17
Esophagectomy
17
Surgical Procedures, Operative
16
Radiation
16
Docetaxel
16
sintilimab
15
Oxaliplatin
14
130-nm albumin-bound paclitaxel
14
nimotuzumab
11
TP protocol
11
S 1 (combination)
11
Radiotherapy, Intensity-Modulated
11
Cetuximab
11
Capecitabine
11
Albumin-Bound Paclitaxel
10
apatinib
9
Leucovorin
9
Immune Checkpoint Inhibitors
8
nedaplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Squamous Cell Carcinoma
×
Panitumumab
×
Clear all
NCT01627379
2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3
Terminated
300 enrolled